Please login to the form below

Not currently logged in
Email:
Password:

leukemia

This page shows the latest leukemia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Amgen has gained EU marketing approval to extend use of Blincyto (blinatumomab) in children with acute lymphoblastic leukemia (ALL), putting it into direct competition with Novartis’new CAR-T treatment Kymriah.

Latest news

More from news
Approximately 5 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There are also global direct-to-patient access programmes for Gleevec and Tasigna, life-saving therapies for chronic myeloid leukemia and gastrointestinal stromal tumours.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics